Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring

Journal of Glaucoma

Volumn 20, Issue 8, 2011, Pages 502-508

  Hermann, Manuel Marcel ^a   Bron, Alain Marie ^b   Creuzot Garcher, Catherine P ^b   Diestelhorst, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

adherence; brimonidine; compliance; glaucoma; monitoring

Indexed keywords

BRIMONIDINE; EYE DROPS; PROSTAGLANDIN; TIMOLOL;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DEVICE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRY EYE; ELECTRONIC MONITORING; ELECTRONICS; ERYTHEMA; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MALE; MEDICAL TECHNOLOGY; MIGRAINE; MONOTHERAPY; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG MONITORING; FEMALE; GLAUCOMA, OPEN-ANGLE; HEALTH BEHAVIOR; HUMANS; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; QUINOXALINES; TONOMETRY, OCULAR;

EID: 80053641080     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181f3eb4a     Document Type: Article

References (25)

1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
2. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120: 1268-1279. (Pubitemid 36105431)
3. Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14:86-90. (Pubitemid 36584227)
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713. (Pubitemid 34620348)
5. Friedman DS, Nordstrom B, Mozaffari E, et al. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005;112: 1500-1504. (Pubitemid 41725403)
6. Kooner KS, Albdoor M, Cho BJ, et al. Risk factors for progression to blindness in high tension primary open angle glaucoma: comparison of blind and nonblind subjects. Clin Ophthalmol. 2008;2:757-762.
7. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12: 393-398. (Pubitemid 37237370)
8. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953-961. (Pubitemid 40797446)
9. Wang PS, Benner JS, Glynn RJ, et al. How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharma-coepidemiol Drug Saf. 2009;13:11-19. (Pubitemid 38159264)
10. Dietlein TS, Jordan J, Dinslage S, et al. What do glaucoma specialists know about their patients. Graefes Arch Clin Exp Ophthalmol. 2006;244:859-862. (Pubitemid 44103334)
11. Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431-436.
12. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthal-mol. 2005;140:598-606.
13. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol. 2006;141:S28-S33. (Pubitemid 43028477)
14. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol. 2005;16:114-121. (Pubitemid 43790804)
15. Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101: 515-523. (Pubitemid 16114195)
16. Kass MA, Gordon M, Morley RE Jr, et al. Compliance with topical timolol treatment. Am J Ophthalmol. 1987;103: 188-193. (Pubitemid 17005483)
17. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116: 191-199.
18. Hermann MM, Diestelhorst M. Microprocessor controlled compliance monitor for eye drop medication. Br J Ophthalmol. 2006;90:830-832. (Pubitemid 43973989)
19. Norell SE, Granstrom PA, Wassen R. A medication monitor and fluorescein technique designed to study medication behaviour. Acta Ophthalmol (Copenh). 1980;58:459-467. (Pubitemid 10082886)
20. Friedman DS, Okeke CO, Jampel HD, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology. 2009;116: 1097-1105.
21. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunc-tive medication use. Am J Ophthalmol. 2007;144:533-540.
22. Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006; 17:190-195. (Pubitemid 43790816)
23. Lux A, Maier S, Dinslage S, et al. A comparative bioavail-ability study of three conventional eye drops versus a single lyophilisate. Br J Ophthalmol. 2003;87:436-440. (Pubitemid 36399032)
24. Wadhwa S, Paliwal R, Paliwal SR, et al. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des. 2009; 15:2724-2750.
25. Ho LY, Camejo L, Kahook MY, et al. Effect of audible and visual reminders on adherence in glaucoma patients using a commercially available dosing aid. Clin Ophthalmol. 2008; 2:769-772.